Search

Your search keyword '"Awad M.M."' showing total 364 results

Search Constraints

Start Over You searched for: Author "Awad M.M." Remove constraint Author: "Awad M.M."
364 results on '"Awad M.M."'

Search Results

8. Oncology clinical trial disruption during the COVID-19 pandemic: a COVID-19 and cancer outcomes study

14. Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression ≥50%

19. EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer

20. OA19.05 Activating MET Tyrosine Kinase Domain Mutations as de Novo Oncogenic Drivers in Non-small Cell Lung Cancer

21. P2.07-03 Factors Associated with Disease Progression after Discontinuation of Immunotherapy for Immune-Related Toxicity in Non-small Cell Lung Cancer

22. MA20.06 Association of TTF-1 Expression with Outcomes to Immunotherapy and KRAS G12C Inhibition in Lung Adenocarcinoma

23. EP10.01-03 A Phase 1/2 Study of REGN5093-M114, a METxMET Antibody-Drug Conjugate, in Patients with MET-Overexpressing NSCLC

24. AI-Derived CT Body Composition in Advanced Non-Small Cell Lung Cancer: A Multicohort Study

26. PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers

29. PP01.17 Sotorasib in Advanced KRAS p.G12C–Mutated NSCLC with Treated or Untreated Brain Metastases: Safety and Efficacy Data from the Global Expanded Access Program (EAP)

30. Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma

33. Nivolumab (NIVO) + doublet de chimiothérapie à base de sels de platine (chimio) versus chimio, en traitement néoadjuvant du cancer bronchique non à petites cellules (CBNPC) résécable (IB-IIIA) : corrélation entre survie sans évènement (EFS) et régression pathologique dans l’étude CheckMate 816

36. Association of Skeletal Muscle Area with Toxicity and Treatment Tolerance in Patients Receiving Chemoradiation for Advanced Lung Cancer

37. A multicentre study of pembrolizumab time-of-day infusion patterns and clinical outcomes in non-small-cell lung cancer: too soon to promote morning infusions

38. Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer

39. OA15.05 HUDSON: An Open-Label, Multi-Drug, Biomarker-Directed Phase 2 Study in NSCLC Patients Who Progressed on Anti-PD-(L)1 Therapy

40. OA12.06 First-Line Pembrolizumab or Placebo Combined with Etoposide and Platinum for ES-SCLC: KEYNOTE-604 Long-Term Follow-Up Results

43. EP08.01-043 Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced Non-small Cell Lung Cancer (NSCLC)

45. MA07.06 Eradicating Drug Tolerant Persisters (DTPs) In EGFR-Mutated Non Small Cell Lung Cancer (NSCLC) By Targeting TROP2

Catalog

Books, media, physical & digital resources